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ABSTRACT: Recent approaches in the treatment of
cancer focus on involving the immune system to control
the tumor growth. The administration of immunotherapies,
like checkpoint inhibitors, has shown impressive results in
the long term survival of patients. Cancer vaccines are
being investigated as further tools to prime tumor-specific
immunity. Biomaterials show potential as adjuvants in the
formulation of vaccines, and biomimetic elements derived
from the membrane of tumor cells may widen the range of
antigens contained in the vaccine. Here, we show how mice
presenting an aggressive melanoma tumor model treated
twice with the complete nanovaccine formulation showed
control on the tumor progression, while in a less aggressive
model, the animals showed remission and control on the tumor progression, with a modification in the immunological
profile of the tumor microenvironment. We also prove that co-administration of the nanovaccine together with a
checkpoint inhibitor increases the efficacy of the treatment (87.5% of the animals responding, with 2 remissions)
compared to the checkpoint inhibitor alone in the B16.OVA model. Our platform thereby shows potential applications as
a cancer nanovaccine in combination with the standard clinical care treatment for melanoma cancers.
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The recent reports about the increase in the overallsurvival of cancer patients treated with immunother-apeutics, in particular checkpoint inhibitors, adoptive
cell transfer, and chimeric antigen receptor T cells, rekindled
the interest in the development of prophylactic and therapeutic
cancer vaccines.1−3 Biomaterials are currently being inves-
tigated for the formulation of micro- and nanoparticulate
vaccines that enable the co-delivery of antigens and
adjuvants.4,5 Alternatively, biomaterials have been exploited
in drug delivery systems for immune checkpoint inhibitors,
including microneedles, scaffolds, micro- and nanoparticles,
and platelets.6−10 Furthermore, the materials themselves may
present immunogenic properties leading to the stimulation of
toll-like receptors and danger associated molecular pathways,
and consequently to the activation of antigen presenting cells
(APCs).11 Among the biomaterials assessed, porous silicon
(PSi) micro- and nanoparticles promote the maturation of
immature dendritic cells (DCs) to a mature phenotype, with a
shift in the cytokine profile toward a Th-1 biased profile,
enabling the priming of cytotoxic T lymphocytes.12−14 The
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semi-synthetic modification of the biocompatible polymer
dextran with acetal groups yields a pH-sensitive polymer
characterized by immunostimulatory properties.15,16 Thermally
oxidized PSi (TOPSi) nanoparticles and acetalated dextran
(AcDEX) formulated into a nanocarrier by nanoprecipitation
in glass capillary microfluidics induced the activation of
peripheral blood monocytes in vitro, showing a potential
application as a biomaterial-based platform for cancer
vaccines.12
One of the reasons behind the failure of many vaccines in
clinical trials is the choice of the antigenic component: Tumor
associated antigens (TAAs) or cancer-testis antigens are
expressed also by other healthy tissues, thus the likelihood of
depletion of highly reactive T cells by central tolerance to
avoid autoimmunity is high.2,17,18 On the contrary, tumor-
specific antigens, or neoantigens, are derived from point
mutations and are expressed only in cancer cells.19,20 The
possibility of eliciting a stronger immune response is thereby
higher upon stimulation with neoantigens compared to
TAAs.21 Recently, vesicles derived from the membranes of
cancer cells were proposed as an alternative source of antigens
and neoantigens for the formulation of cancer vaccines.22 The
advantage of using this antigenic source resides in the
multiplicity and complexity of the antigens delivered to the
APCs.23 We have previously investigated the feasibility of this
antigenic source in vitro, in a multistage delivery system
composed of a core made of adjuvant biomaterials, which was
further coated with a layer of cell membranes (cancer cell
membranes, CCM) by extrusion through a polymeric
membrane.12
The immunosuppressive environment of the tumor micro-
environment may reduce the potency of the immune response
evoked by a therapeutic vaccination.24 To tackle this problem,
we hyphothesized that a biohybrid vaccination platform
(Scheme 1) should synergize with checkpoint inhibitors,
such as CTLA-4 blocking antibodies. For this reason, we
focused on the improvement of the immune infiltration and
antigen-experience of T cells through an enhanced activation
of APCs in the tumor surroundings. Furthermore, we
hypothesize that a combinatorial therapy between our
nanovaccine and an anti-CTLA4 antibody can enhance the
efficacy of the vaccination due to the mechanism of action of
the checkpoint inhibitor on the central regulation of the T cell
activation. In this study, we assess the nanovaccine and the
combination of anti-CTLA4 antibody administered concur-
rently with the vaccination on the efficacy of the treatment and
on the priming of the immune response in vivo. We first
evaluated the efficacy of the vaccination alone on the growth of
an aggressive melanoma murine model, investigating also the
changes in the immune profile at the tumor site. Subsequently,
we assessed the synergistic potential of the combinatorial
therapy with the immune checkpoint inhibitor on the growth
of established tumors and on the infiltration of activated
immune cells in the tumor microenvironment.
RESULTS
Tumor Membrane-Coated Nanoparticles: Cytocom-
patibility and Immunostimulatory Properties. We first
evaluated the cytocompatibility of the system, tumor-
membrane-coated (TOPSi@AcDEX@B16.OVA) nanopar-
ticles (NanoCCM), onto an immortalized murine immune
cell line, JAWS II, as such or in the presence of two different
concentrations (1 and 10 μg/mL) of the murine anti-CTLA4
antibody. The formulation was assessed in a range of
concentrations from 25 to 500 μg/mL for 24 h. As shown in
Figure 1A, after 24 h, NanoCCM particles are highly
cytocompatible over the whole range of concentrations
assessed, inducing a slight cell proliferative effect, as reported
also in previous works.5,12 The incubation of the nanovaccine
together with the checkpoint inhibitor at the concentrations of
1 and 10 μg/mL did not alter the safety profile of the
formulation. Thereby, we selected the concentration of 1 μg/
mL of anti CTLA-4 antibody for further in vitro studies. After
48 h, the particles induce a dose-dependent decrease in the
cellular viability for the highest concentrations assessed (250
and 500 μg/mL).
In the following assay, we assessed the immunostimulatory
properties of the nanovaccine by incubating the nano-
formulation, at the concentration of 100 μg/mL, with JAWS
II and, subsequently, analyzing the activation profile of the cells
from the expression of co-stimulatory signals (CD80 and
CD86). As shown in Figure 1B, the nanovaccine, after 48 h of
incubation, stimulated the expression of CD86 to levels
comparable to those of lipopolysaccharide (LPS), proving the
ability of the formulation to induce the maturation of APCs.
The inclusion of the checkpoint inhibitor does not change the
level of CD86 presented by the cells. The peak of the
immunostimulatory effect of the formulation is reached at 48
h, and at 72 h, there is a decrease in the expression of the
receptor, when compared to LPS, while still being significantly
higher than the control in medium. As for the expression of
CD80, at 48 h, there is no difference among all the samples,
while for 72 h, the nanosystems present levels of expression
even lower than the negative control. However, at 48 h, the
incubation of the cells with NanoCCM resulted in a significant
increase in the number of double positive cells, when
compared to LPS. When the checkpoint inhibitor was added,
the percentage of double positive cells decreased. After 72 h,
the immunostimulating effect of the NanoCCM formulation
fades, when compared to LPS. Interestingly, in the presence of
the ICI, the cells displayed a higher percentage of double
positive cells compared to the nanosystem alone. Moreover, we
evaluated the mechanism of activation of APCs by determining
the effect of the particles on the secretion of TNF-α by human
peripheral blood monocytes; the effect of the cytokine was
Scheme 1. Illustration of the Multistage Nanovaccine
Platforma
aA PSi core (porous brown core) was encapsulated within a layer of
AcDEX (light blue) using glass capillary microfluidics. Then, the
nanoparticles were enveloped by a layer of cancer cell membrane
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studied by co-culturing the medium of peripheral blood
monocytes with Ramos Blue. As presented in Figure S1, only
TOPSi NPs induce the secretion of TNF-α, while when the
particles were encapsulated within the polymeric layer and
then enveloped within the CCM, there was no secretion of
TNF-α. These results are in agreement with what was
previously reported elsewhere.12,13
Moreover, we evaluated the ability of the nanovaccine to
mediate the cross-presentation of antigens to MHC-I. As
presented in Figure S2, the incubation of JAWS-II cells with
Figure 1. Tumor-membrane coated TOPSi@AcDEX nanovaccines are cytocompatible and induce the maturation of murine APCs in vitro.
(A) Cell viability (%) of JAWS II cells incubated with the tumor-membrane-coated TOPSi@AcDEX nanovaccine (NanoCCM) for 24 h (left)
and 48 h (right), as such or in the presence of two different concentrations of a murine anti-CTLA4 antibody. Cells incubated in 10%
medium and in Triton X-100 1% represent the negative and positive controls. (B) Percentage of CD80, CD86, and double positive JAWS II
cells after 48 h (top) and 72 h (bottom). JAWS II cells were incubated with APC antimouse CD80+ antibody or PerCP-Cy 5.5 antimouse
CD86+ antibodies, and the expression of the receptors was evaluated by flow cytometry. The cells were incubated with NanoCCM at the
concentration of 100 μg/mL for 48 and 72 h. Cells incubated with medium and cells incubated with LPS represent the negative and positive
controls, respectively. The results are expressed as mean ± SD (n > 3) and were analyzed with two-way ANOVA followed by Bonferroni
post-test. *p < 0.05, **p < 0.01, and ***p < 0.001.
ACS Nano Article
DOI: 10.1021/acsnano.8b09613
ACS Nano 2019, 13, 6477−6490
6479
NanoCCM (wrapped with membrane derived from B16.OVA
cells and spiked with SIINFEKL-cell penetrating peptide,
CPP) induced the presentation of SIINFEKL on MHC-I. The
cell membrane vesicles alone induced the cross-presentation,
while the JAWS-II cells incubated with the polymer alone did
not present any SIINFEKL peptide. Next, we investigated the
possibility that the presence of the cell membrane wrapped
around the particles could induce a partial cross-dressing with
the APCs. For this, we prepared CCM and NanoCCM samples
wrapped with the membrane of a BALB/c cell line (4T1).
JAWS-II cells (C57BL/6 lineage) were pulsed with these
formulations, and we assessed the percentage of the MHC-I H-
2Kd molecule presented on the cells. As shown in Figure S3,
the incubation with both CCM and NanoCCM results in a
partial cross-dressing of the membranes. Finally, to clarify the
vaccination mechanism of the biohybrid nanovaccine,
splenocytes derived from OT-I mice were incubated with
JAWS-II cells pulsed with the formulation (B16.OVA
membrane spiked with SIINFEKL-CPP). The supernatant
was collected and analyzed for the content in IFN-γ. As
presented in Figure S4, APCs pulsed with the formulations
presenting OVA and SIINFEKL (namely CCM and
NanoCCM) activated OT-I cells with the secretion of IFN-γ.
The nanosystem induced a statistically higher activation
compared to CCM alone, despite the higher level of cross-
presentation achieved with CCM.
Overall, we proved the cytocompatibility of the system and
its ability to induce the maturation of APCs, with an increase
in the expression of the co-stimulatory signals CD80 and
CD86 to levels comparable to those of the positive control
(cells activated by LPS). Moreover, the nanovaccine promotes
the cross-presentation of antigens in APCs and the subsequent
activation of T cells. Our system, thereby, has properties as
adjuvant in a complete nanovaccine formulation.
Biohybrid Nanoparticles Increase the Response
Against B16F10 Melanoma by Modulating the Infiltra-
tion of Dendritic Cells and Cytotoxic T-Lymphocytes. In
these experiments, we tested our biohybrid platform by
engrafting C57 mice with the highly immune suppressive
B16F10 tumors. Hence, we treated the mice with TOPSi@
AcDEX nanoparticles extruded with a homologous membrane
(B16F10 cells) to promote an anti-tumor immune response.
The percentage of mice responding to the therapy, defined as
mice showing a tumor volume lower than 300 mm3, was 12.5,
28.6, and 33.3% in the mock, CCM, and AcDEX groups
respectively (Figure 2A). Although modest, we registered an
increase in the number of responding mice in the group treated
with NanoCCM (44.4%). In a comparison between the tumor
volume in different groups (Figure S2), no significant
difference was found between the three treatment groups.
We hypothesize that the intrinsic aggressiveness of the B16F10
tumor model prevents the possibility to fully evaluate the
priming of a tumor-specific immune response. However, the
efficacy of the treatment was limited to less than half of the
cohort of animals, providing indications for future improve-
ments of the formulation. Next, we investigated by flow
Figure 2. Biohybrid nanovaccines increase the response to aggressive B16F10 established tumors and induce immunological changes into
the tumor microenvironment. Female C57BL6/J mice (n = 7/8) were engrafted with 1.0 × 105 B16F10 melanoma cells on the right flank.
After 6 days, the mice were randomized into 4 groups and treated subcutaneously with 5.4% isotonic glucose solution (mock group), bare
TOPSi@AcDEX nanoparticles (AcDEX group), processed tumor-membrane vesicles (CCM group), or tumor-membrane-coated TOPSi@
AcDEX nanovaccines (NanoCCM group). A second treatment injection was performed in the peri-tumoral region at day 13. (A) Single
curves of each tumor for each group. In this tumor model, responders (green curves) are defined as mice that show an absolute tumor
volume lower than 300 mm3. (B) Tumors were collected and stained for the presence of DCs (CD11c+). (C) The activation state of the DCs
was characterized by using CD80 and CD86 surface markers. The presence of TILs was also assessed. (D) Flow cytometry was used to detect
intratumoral cytotoxic T-cells (CD3+CD8+). (E) The activation state of the TILs was investigated by analyzing the presence of the PD-1
marker. All graphs represent mean ± SEM. Statistical analysis was performed with unpaired Student’s t-test or one-way ANOVA; the levels
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cytometry whether or not the treatment with NanoCCM could
affect the immune infiltration of cells into the tumor. Mice
receiving NanoCCM showed a trend toward an increased
infiltration of DCs (defined as CD11c+ cells; Figure 2B) with a
large portion of those being activated and mature (CD80 and
CD86 double positive cells; Figure 2C). In addition, we
analyzed the infiltration by T-cells to understand if the effect of
NanoCCM treatment on DCs would result also in an increased
presence of tumor-infiltrating lymphocytes (TILs). Consistent
with our hypothesis, we found that tumors of mice receiving
the biohybrid nanoparticles were highly infiltrated by cytotoxic
T-cells (defined as CD3+CD8+ cells; Figure 2D). Remarkably,
only the treatment with NanoCCM was able to increase the
presence of antigen-experienced TILs when compared to a
mock (p < 0.05), as proven by the higher presence of PD-1+ T-
cells (Figure 2E). However, the analysis of the PD-1+ T-cells
provides only information on the level of the antigen
experience of the T-cells, but not on the specific antigen the
cells have been primed for.25−27
In line with our aim to increase the response to
immunotherapy, we explored the correlation between immune
infiltration of tumors and tumor size among all groups. Our
analysis revealed that mice with smaller tumors showed
significantly higher levels of TILs within the tumors (Figure
3A); in addition, PD-1+ TILs were enriched into the tumors of
the mice with a low tumor burden (Figure 3B). The presence
of DCs and their activation state also clearly distinguished
nonresponders from responders (Figure 3C,D). Interestingly,
the data from two responders scored higher than the
responders in Figure 3A−C, leading us to hypothesize a
trend with different levels of activation of the immune system
within the responders court. However, the study was not
powered enough to show statistical significance. Finally, we
studied the correlation between tumor volume and immune
infiltration, and we found that an exponential model would
better describe the relationship between those two parameters.
In fact, for all of the tested correlations, we achieved statistical
significance (p < 0.05) and a relatively good fitting to an
exponential model, suggesting that the correlation is unlikely to
be linear, but it rather follows an exponential model since anti-
tumor responses are likely the result of several co-operating
factors (Figure 3E).
Biohybrid Nanoparticles Prime Tumor-Specific Im-
mune Responses with Rejection of Established Mela-
nomas. In this set of experiments, we investigated the in vivo
efficacy of our cancer nanovaccine platform in a less aggressive
setting. To this end, we engrafted C57BL6 immunocompetent
mice with the B16.OVA tumor cells. Mice received treatments
at 6 and 13 days after tumor engraftment. As shown in Figure
4A, treatment with only immunogenic TOPSi@AcDEX (i.e.,
Figure 3. Correlation between response to immune therapy and changes in the tumor microenvironment of melanoma tumors. The flow
cytometry data presented in Figure 2 were used to perform an explorative analysis to correlate infiltration of immune cells to tumor size.
Responding (red data points) and nonresponding (black data points) mice were grouped from all treatment groups and analyzed for the
intratumoral presence of (A) cytotoxic T-cells, (B) antigen-experienced cytotoxic T-cells, (C) DCs, and (D) activated and mature DCs. The
statistical analysis was performed with unpaired Student’s t-test, and the levels of significance were set at *p < 0.05 and **p < 0.01. The flow
cytometry data for every mouse are normalized against the tumor volume of that mouse. (E) To evaluate the correlation between
immunological features and tumor response, data from all mice were pooled, and the correlation was tested with Pearson’s correlation test
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AcDEX) nanoparticles or tumor membrane (i.e., CCM)
resulted in modest responses in 50% and 66% of the treated
mice, respectively. However, mice treated with the TOPSi@
AcDEX particles coated with the tumor membrane (hereafter
named NanoCCM) responded in 71% of the cases.
Interestingly, this was the only group where we registered
complete responses in 28.5% (2 out of 7) of the mice (Figure
4B). The average volume curves for all of the groups are
presented in Figure S3, highlighting the synergistic effect of the
core and CCM-layer over the single components. These results
are consistent with our previous experiments and highlight the
potential of our nanoplatform as a therapeutic cancer vaccine,
since only two therapeutic injections of NanoCCM were
necessary to achieve significantly better results compared to
the mice in the control groups.
Next, we investigated if NanoCCM could modulate the
activation of DCs in this melanoma model. Consistent with the
in vitro studies on APCs and with the results from the study in
the more aggressive tumor model, the tumor tissues of mice
receiving any of the immunotherapy treatment featured an
increased number of tumor infiltrating DCs (tDCs defined as
CD11c+ CD11b+; Figure 5C). However, we found substantial
differences in the quality and activation state of DCs (Figure
5D). The AcDEX nanovaccine formulation proved to be the
best in inducing the expression of the activation markers on the
surface of DCs.
Flow cytometry analysis revealed an increase in the
percentage of the total activated DCs (either CD80+, CD86+,
or double positive CD80+CD86+ cells), thereby proving
AcDEX to be an excellent adjuvant. Nevertheless, when we
studied the distribution of the activated population into the
whole DCs population, the tumors of mice treated with
NanoCCM presented the highest percentage of double
positive CD80+CD86+DCs (39.36%), which represent the
most efficient maturation status of an APC. We conclude that
while all of the treatments induced a degree of maturation of
DCs, only NanoCCM treatment was able to reshape the
distribution between different maturation statuses, resulting in
a lower percentage of early activated DCs (6.38% of CD86+
cells) and a higher percentage of fully activated DCs (39.36%
of CD80+CD86+ cells) compared to the other groups (Figure
5E). It is noteworthy to stress that there was only a limited
amount of tissue recovered in the animals cured after
treatment with NanoCCM.
Biohybrid Nanoparticles Increase the Efficacy of
Immune Checkpoint Blockade against Established
Melanomas. In line with the efforts to convert “cold tumors”
into “hot tumors”, we hypothesized that the biohybrid
nanovaccine platform developed here would increase the
response rate to checkpoint inhibition, especially increasing the
number of the overall responders. To this end, we investigated
how the co-administration of anti-CTLA4 antibody, known to
potentiate the priming of T-cells, would increase the efficacy of
our cancer nanovaccine platform.
Established murine melanoma tumors (B16.OVA) were
treated at multiple time points (Figure 6A, black arrows) to
prime and boost an antigen-specific response. The NanoCCM
treatment was combined with intraperitoneal administration of
aCTLA4 antibody (Nano-CCM + aCTLA4 group) and
compared with aCTLA4 monotherapy. The aCTLA antibody
was selected for the evaluation of the combinatorial therapy
due to its mechanism of action that stimulated the priming of
Figure 4. Biohybrid nanoparticles increase the anti-tumor response and rejection rate against established B16.OVA tumors. Female
C57BL6/J mice were engrafted with 2.5 × 105 B16.OVA cells on the right flank. After 6 days, mice were randomized into 4 groups and
treated subcutaneously with 5.4% isotonic glucose solution (Mock group), bare TOPSi@AcDEX nanoparticles (AcDEX group), processed
tumor-membrane (CCM group), or tumor-membrane-coated TOPSi@AcDEX nanoparticles (NanoCCM group). A second treatment
injection was performed in the peri-tumoral region at day 13. (A) The single curves of each tumor for each group. Responders (green
curves) are defined as mice that show an absolute tumor volume lower than 400 mm3. (B) The percentage of complete responses (i.e., cured
mice) observed in each group.
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T cells at a systemic level, different for aPD-L1 antibodies.28
We hypothesize that our nanovaccine is priming an immune
response against neoantigens, thereby a combo therapy with an
aCTLA4 antibody is most likely to result in a synergistic effect.
As expected, blocking the aCTLA4 inhibitory pathway slowed
the growth of tumors compared to treatment with a 5.4%
glucose isotonic solution (mock group). Mice receiving the
combination treatment registered a significant reduction in
tumor volumes compared to both mock and aCTLA
monotherapies, as shown by the growth curves (Figure 6A)
and their area under the curve (Figure 6B). One mouse using
the aCTLA4 monotherapy experienced a complete response,
however the combo therapy NanoCCM + aCTLA4 was able to
induce complete responses in 25% of treated mice (Figure
6C). Consistent with the clinical data, while checkpoint
inhibition slowed the growth of tumors, the overall benefit was
inconsistent with few significant responses (Figure 6D, central
panel). On the contrary, we recorded an increase in the
number of responders among mice receiving the combination
of aCTLA4 and NanoCCM cancer vaccines (87.5% of mice
responded to the therapy).
Immunological analysis showed that aCTLA4 monotherapy
was not able to induce infiltration and expansion of CD8+ T
cells into tumors of mice. However, the combination of cancer
nanovaccine and the checkpoint inhibition induced a
considerable increase in the number of tumor infiltrating
cells (Figure 7A), supported by an increase in myeloid APCs
(Figure 7B,C) into the tumors. When compared to a mock,
both immunotherapies were able to increase the activation of
DCs (Figure 7D). As shown in Figure 7E, the combination of
aCTLA4 and NanoCCM reduced the fraction of early
activated DCs (35.80%) compared to a mock (62.98%) and
aCTLA monotherapy (47.68%). The combination group also
increased the percentage of CD80+CD86+ double positive DCs
(red portion of cake graphs in Figure 7E).
DISCUSSION
Tumor growth results in a continuous apoptosis/necrosis of
tumor cells followed by their replacement during the invasion
process.29 For this reason, the immune system is exposed to
tumor antigens constantly.18,30 However, this process lacks a
proper co-stimulation and pro-inflammatory signals, as the
tumor microenvironment is heavily immunosuppressive.31,32
Therefore, antigen presentation is usually ineffective, and it
rarely results in spontaneous and beneficial anti-tumor
immunity.33 Therefore, it is crucial to provide the immune
Figure 5. In vivo immunological effects of TOPSi@AcDEX-based cancer vaccines. Individual tumor samples were collected at the end point
for each mouse, and the tumor-infiltrating cells were analyzed. (A) The ratio of CD8+ to CD4+ TILs is reported for every group. (B) The
percentage of OVA-specific CD8+ TILs was measured by pentamer staining of tumor samples. The percentages were normalized by the
tumor volume of each mouse. Then, each data set was normalized against a mock to measure the fold-increase over the mock group. By
definition, the mock group is 1. (C) DCs were defined as CD11c+ and CD11b+ double positive cells within the tumor microenvironment.
Data were normalized to the tumor volume of every mouse to take into account the different sizes of tumor masses at the moment of tissue
collection. (D) Total percentages of activated and mature DCs, defined as either CD86+ (gray) or CD80+ (black) single positive or CD86+
CD80+ double positive cells (red). (E) Relative distribution and polarization of the DCs subsets for each group. All graphs represent the
mean ± SEM. Statistical analysis done with unpaired Student’s t test; *p < 0.05 and **p < 0.01.
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system with adjuvants capable of optimizing the maturation of
APCs, which are at the center of every cancer vaccine
approach.34 For this reason, cancer nanovaccines represent an
attractive choice to stimulate anti-tumor responses in a specific
and efficient manner.35 In this work, we describe the anti-
tumor efficacy and immunological effects of our cancer
nanovaccine platform based on biohybrid (TOPSi@AcDEX)
nanoparticles coated with membranes derived from tumors
cells. The nanovaccine promotes the activation of APCs
(JAWS II cells) due to the biomaterials employed in the
formulation of the system. TOPSi nanoparticles promote the
maturation of immature monocyte-derived DCs due to their
fast biodegradation in physiological fluids, with the release of
silicic acid.13 AcDEX increases the expression of major
histocompatibility complexes due to its rapid degradation in
acidic conditions.15 The combination of the two biomaterials
into one nanovaccine formulation primed a Th-1 biased
immune response in vitro over human peripheral blood
monocytes.12 The biohybrid nanovaccine, as result of the
adjuvant properties of the biomaterials, can promote cross-
presentation of the antigens presented on the cell membrane.36
The antigens and maturation cues provided to the APCs result
in a complete immune response, with the activation of CD8 T
cells and the secretion of IFN-γ.
Moreover, an alternative mechanism of antigen presentation
to memory T cells takes place through the cross-dressing of
membranes.37,38 The pulsing of APCs with the nanovaccine
results in the cross-dressing of the membrane used to wrap the
particles with the membrane of the APCs.
One of the main advantages of our nanoplatform is the
possibility to induce immune responses against multiple tumor
antigens, without the need to select specific peptides. Hence,
tumor-membrane-coated nanoparticles share some similarities
with whole tumor vaccines. Whole tumor vaccines have been
studied in preclinical and clinical settings,39,40 and the main
advantage of this approach is the ability to induce responses
against a wide variety of antigens, thus overcoming the difficult
selection of specific peptides.41,42 These classes of nano-
vaccines can be combined with cytokines to support the
priming of cytotoxic T-lymphocytes (CTLs).43 For instance,
interleukin (IL) 2 has been used in co-administration with
tumor cells to sustain the proliferation of CTLs, resulting in
responses in 72% of treated patients.44
Figure 6. The efficacy of the anti-tumor effect of the vaccination with biohybrid nanoparticles is increased by co-administration of CTLA-4
checkpoint inhibitor. Female C57BL6/J mice were engrafted with 2.5 × 105 B16.OVA cells on the right flank. After 6 days, mice were
randomized into 3 groups and treated subcutaneously with 5.4% isotonic glucose solution (mock group), intraperitoneally with 100 μg of
anti-CTLA-4 monoclonal antibody, or with tumor-membrane coated TOPSi@AcDEX nanoparticles (NanoCCM) + anti-CTLA4 antibody.
Two more rounds of treatment were performed at days 13 and 15 post-tumor engraftment. (A) Tumor volumes at each time point were
normalized against the initial tumor volume. Then tumor growth curves were built by plotting the mean ± SEM of tumor volumes for each
group. (B) The area under the curve (AUC) of the growth curve of each mouse is plotted in the box and whiskers graphs (Tukey’s
representation). (C) The number of complete responses (i.e., cured mice) for each group is reported. (D) Single growth curves are reported
for each group. Responders (green curves) are defined as mice which show an absolute tumor volume lower than 400 mm3. The percentage
of responders in the group is reported next to each graph. Statistical analysis of tumor growth was done by two-way ANOVA with Tukey’s
multiple comparison correction. The AUCs were analyzed by unpaired Student’s t test; *p < 0.05; **p < 0.01; ****p < 0.0001.
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We were able to induce a higher number of responses in a
poorly immunogenic tumor model, observing a change in the
infiltration of both DCs and T-cells (Figure 2). The
modulation of the tumor microenvironment is a key aspect
for the success of immunotherapy, and immune profiling is
gaining momentum since it is often able to define patients who
would respond to the therapy. While some studies point to the
mutational load of tumors, which would help immune cells to
recognize malignant ones,45 other studies point toward what
has been defined as “immune-contexture”.46 The infiltration of
tumor tissues by tumor cells and the presence of adaptive
immunity (pre-existing or newly induced) are important
prognostic factors when considering combination therapies.47
Our biohybrid nanoparticle (Figure 2) was able to increase the
presence of TILs with an activated state (PD-1+), and this can
potentially improve the response to the CTLA-4 blockade, as
consistently described in a recent study elsewhere.48
We demonstrated that the combination of tumor membrane
with proper immunologically active nanomaterial leads to
better anti-tumor responses in B16.OVA melanoma models,
with higher rejection rates among treated animals (Figure 4).
We found an increased activation of APCs and, in particular,
DCs after the treatment with NanoCCM (Figure 5D). The
treatment with vesicles isolated from the tumor cells increases
the number of the APCs in the tumor tissue, but is not
sufficient to induce their activation without adding any
adjuvant,22 while the nanoparticles alone induce the matura-
tion of APCs that, however, are not tumor specific.15
In the last five years, the immunotherapy field has gained
new attraction due to the success of immune checkpoint
inhibitors (ICIs). This class of antibodies blocks inhibitory
pathways that tumor cells exploit to inactivate cytotoxic
CTLs.49−51 However, while very effective, the number of
patients that benefit from the expensive treatment with ICIs
remains limited. In fact, resistance mechanisms reduce the
Figure 7. Biohybrid nanoparticles favor the efficacy of the anti-CTLA-4 therapy by reshaping the tumor microenvironment. Individual tumor
samples were collected at the end point for each mouse, and the tumor-infiltrating cells were analyzed. (A) The percentage of CD8+ TILs
was normalized against the tumor volumes of each mouse to account for the size of tumor masses. (B) Infiltration of myeloid cells (defined
as CD11b+ cells) into the tumor microenvironment. (C) DCs were defined as CD11c+ and CD11b+ double positive cells within the tumor
microenvironment. Data were normalized against the tumor. (D) Total percentages of activated and mature DCs, defined as either CD86+
(gray), CD80+ (black) single positive, or CD86+ CD80+ double positive cells (red). (E) Relative distribution and polarization of the DCs
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response rate,52 and the absence of antigen-specific T cells into
the tumor microenvironment represents the biggest limitation.
In addition, tumors with poor T cell infiltration, often defined
as “cold tumors”, are resistant to checkpoint therapy, as ICIs
do not create immune responses, but they simply protect
primed T cells from inactivation.53−55 Recently, biomaterials
have been developed for the local delivery of ICIs, in an effort
to reduce side effects and to improve the efficacy.6−11
Therefore, in line with the efforts to convert “cold tumors”
into “hot tumors”, we hypothesized that the biohybrid
nanovaccine platform developed here would increase the
response rate to checkpoint inhibition. We observed that
blocking the inhibitory pathway with an anti-CTLA4 poorly
improves the response to aggressive established tumors, as
shown in Figure 6. However, an increase in the number of
responders was achieved when the anti-CTLA-4 antibody was
combined with the biohybrid nanovaccine platform. The
nanovaccine platform provided a strong maturation signal to
DCs that was converted into an increased presence of CD8+ T-
lymphocytes into the tumor microenvironment, synergizing
with anti-CTLA-4 treatment (Figure 7).
We would like to emphasize that the results herein presented
are limited to murine melanoma models, implying that the
efficacy of the treatment may be different in less immunogenic
tumor models. Moreover, the results of the immunological
profiling can be biased by the reduced tumor volume or by the
rejection (no tumor retrievable) in the group treated with the
complete formulation. We would also like to stress the absence
of a direct causative relationship between the phenotypical
changes recorded in the tumor microenvironment and the
efficacy of the treatments. The analysis of the presentation of
co-stimulatory signals by DCs does not represent per se a
justification to affirm the presence of an immune response
induced by the nanovaccine. Further studies are needed to
evaluate the in vivo mode of action of the nanovaccine,
analyzing in particular the molecular and functional changes
induced in APCs.
CONCLUSION
In summary, the biohybrid nanovaccine is able to elicit an anti-
tumor immune response in aggressive melanoma models and
to modify also the immunological profile within the tumor
microenvironment. The administration of the vaccine
enhances the activation of APCs, leading to an increased
priming of CD8+ T cells. Moreover, the combination therapy
with the administration of the nanovaccine platform and a
checkpoint inhibitor improves the anti-tumor efficacy of the
checkpoint inhibitor alone. The versatility of the biohybrid
(tumor-membrane-coated) nanoparticle platform represents an
advantage in the personalized medicine field, where tumor
membranes can be obtained from patient’s biopsies in order to
eliminate histocompatibility problems and target patient-
specific neo-antigens present in the tumor cells. The
production of the nanovaccine is faced with the scale up
from a laboratory to clinical batches. However, the scaling up is
facilitated by the production of the particles by microfluidics,
in single devices that may produce up to 700 g/day.56 In
addition, this class of cancer nanovaccines can be easily
combined with checkpoint inhibitors in order to protect
primed T cells from inactivation, increasing the rate of
responders to standard care immunotherapies available on the
market.
MATERIALS AND METHODS
Cell Lines and Reagents. The murine melanoma cell line
B16.OVA, a mouse melanoma cell line expressing chicken ovalbumin
(OVA), was kindly provided by Prof. Richard Vile (Mayo Clinic,
Rochester, MN, USA). This cell line was cultured in Roswell Park
Memorial Institute (RPMI) 1640 media (Gibco, Thermo Fisher)
supplemented with 10% of fetal bovine serum (FBS, Gibco, Thermo
Fisher), 1% of L-glutamine (Glutamax, Gibco, Thermo Fisher), and
1% of penicillin/streptomycin (Gibco, Thermo Fisher). To ensure the
expression of OVA protein and the selection of OVA-positive clones,
cells were cultured with geneticin antibiotic at a 10% concentration
(G418, Gibco, Thermo Fisher). B16F10 cells were cultured as
B16.OVA, without the addiction of geneticin to the flasks. B16.OVA
and B16F10 cells were used both as source of the membranes to coat
the system and as tumor models implanted in the animals. JAWS II
(ATCC CRL-11904) was used to evaluate the cytocompatibility and
the immunostimulative properties of the system in the presence of the
check-point inhibitor. JAWS II cells were cultured in 20% α-modified
Eagle’s medium (aMEM, HyClone, USA) supplemented with 5 ng/
mL of murine GM-CSF. OT-1 splenocytes were isolated from 4−8
week old C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-1) mice (The
Jackon Laboratories) and frozen at −80 °C until use. The splenocytes
were then thawed in lymphocyte media (RPMI supplemented with
10% of FBS, 20 mmol/L L-glutamine, 1% of penicillin/streptomycin,
15 mmol/L HEPES, 50 μmol/L β-mercaptoethanol, 1 mmol/L Na
pyruvate, 160 ng/mL murine IL-2, and 0.3 μg/mL anti-CD3 antibody
clone 145−2C11).57 In vivo Mab anti-CTLA-4 antibody was
purchased form Bio X Cell (West Lebanon, NH, USA).
Animal Experiments. C57BL/6J mice were obtained from
Scanbur (Denmark) at 4−6 weeks of age. Mice were kept in air-
isolated cages with unlimited access to food. All procedures were
carried out under sterile conditions. Mice were anesthetized using
isofluorane vaporizers. Subcutaneous tumor models were developed
by injecting either 1 × 105 or 2.5 × 105 B16.OVA tumor cells (when
80% confluent in T175 flasks) in the right flank of each mouse in 100
μL of nonsupplemented RPMI-1640 medium. Details about the
treatment schedule are given in the figure legends. During the
experiments, the tumor volume was recorded every 2 days by using a
digital caliper. Maximum (L) and minimum (l) tumor diameters were
recorded, and tumor volumes were calculated according to the
formula: (L × l2)/2.
All animal experiments were reviewed and approved by the
Experimental Animal Committee of the University of Helsinki and the
Provincial Government of Southern Finland.
Top-Down Production of Thermally Oxidized Porous
Silicon (TOPSi) Particles. The detailed protocol for the preparation
of TOPSi nanoparticles can be found elsewhere.58,59 The anodization
of silicon wafers into a solution of hydrofluoric acid:ethanol (1:1)
introduces pores within the silicon wafer. The porous layer is then
detached, oxidized for 2 h at 300 °C, and milled in ethanol with a
high-energy ball mill to yield nanoparticles. The particles are then
segregated into the different size ranges by centrifugation and kept at
+4 °C in ethanol.
Synthesis of Acetalated Dextran (AcDEX). Acetalated dextran
was synthesized according to the reaction reported elsewhere.12,60,61
Briefly, we added dextran (1 g, MW 9000−11,000 kDa; Sigma-
Aldrich, USA) to a two-neck flask, previously dried, and we purged
the flask with dry N2. Dextran powder was dissolved in anhydrous
dimethyl sulfoxide (10 mL, Sigma-Aldrich, USA) before adding
pyridinium-p-toluenesulfonate (15.6 mg; Sigma-Aldrich, USA) and 2-
methoxypropene (3.4 mL; Sigma-Aldrich, USA). We quenched the
reaction with trimethylamine (1 mL; Sigma-Aldrich, USA) after 1 h,
and we employed H2O (200 mL) to precipitate the modified dextran.
The pellet was centrifuged (10 min, 20,000g) and washed twice with
trimethylamine solution (100 mL; 0.01% v/v; pH 8). Finally, to
remove the residual trimethylamine solution, the powder was vacuum-
dried at 40 °C for 48 h, producing a fine white powder of acetalated
dextran (1.10 g).15
Isolation of Cancer Cell Membranes (CCM) from B16F10
and B16.OVA Cells. We isolated the cell membranes following the
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protocol reported elsewhere.12,22 We cultured the cells as described
above. Upon reaching 80% of confluence, we removed the medium,
washed the cells with 1 × phosphate buffer solution-ethyl-
enediaminetetraacetic acid (PBS-EDTA; pH 7.4) solution, and
detached them using a 0.25% trypsin-PBS EDTA solution (HyClone,
USA). The cells were centrifuged at 409g for 5 min, and the cells were
washed 3 times with 1 × PBS (pH 7.4). Then, we resuspended the
pellet of cells into lysing buffer (20 mM of TRIS HCl; Sigma-Aldrich,
USA; 10 mM of KCl; Sigma-Aldrich, USA; 2 mM of MgCl2; Sigma-
Aldrich, USA; 1 protease inhibitor mini tablet, EDTA free; Pierce,
Thermo Fisher, USA) and pipetted them thoroughly. The cells were
then centrifuged at 3200g for 5 min, the supernatant collected, and
the pellet resuspended again in lysing buffer and pipetted. The cells
were centrifuged a second time at 3200g for 6 min. We pooled the
supernatant and centrifuged it at 20,000g with a TLA 120.2 rotor in a
ultracentrifuge (Optima MAX, Beckmann Coulter, USA) for 20 min.
We then collected the supernatant and centrifuged it at 45,000g for 5
min. The supernatant was then discarded, and we resuspended the
membranes in Milli Q water.
Production of the Nanovaccine Components by Micro-
fluidics Nanoprecipitation and Encapsulation with CCM by
Film Extrusion. The core structure of the formulation was prepared
by nanoprecipitation in a glass capillary microfluidics device, as
reported elsewhere.12 We employed a device presenting a 3D co-flow
geometry for nanoprecipitation. The assembly of the device has been
described elsewhere.62 The inner capillary (ID 580 μm, OD 1 mm;
World Precision Instruments Inc., USA) was pointed with a
micropipette puller (P-97, Sutter Instrument Co., USA) to a diameter
of approximately 20 μm. We then tapered the capillary to enlarge the
diameter to approximately 100 μm. This capillary was then inserted
and aligned coaxially into the outer capillary (ID 1.10 mm, Vitrocom,
USA), and we assembled them in the microfluidics platform. In the
nanoprecipitation technique, the inner and outer solutions are
miscible and are pumped, keeping the flow rates constant, in the
microfluidics device in the same direction. The flow rate of the two
phases was controlled by two pumps (PHD 2000, Harvard Apparatus,
USA), and the liquids were pumped from syringes into the capillaries
through polyethylene tubes. To prepare TOPSi@AcDEX particles, we
resuspend TOPSi particles in an ethanol solution of AcDEX for the
inner phase, while we employed a 1% (w/v) poly(vinyl alcohol)
aqueous solution for the outer phase. We fixed the inner flow rate to 2
mL/h and the other to 40 mL/h. The collection vial was kept under
stirring (approximately 300g), and the collected particles were washed
once with Milli-Q water (12959g, 5 min). Finally, the cell membrane
layer was added on the surface of the particles by film extrusion
through a 0.8 μm filter (Nucleopore Track-Etch Membrane,
Whatman, UK) with an Avanti extruder (Avanti Lipids, USA). The
cell membrane used for the extrusion of the samples was homologous
to the cells used to establish the tumor models, B16.F10 in
experiment 1 and B16.OVA in experiments 2 and 3.
Characterization of the Nanovaccine by Dynamic Light
Scattering (DLS) and Electrophoretic Light Scattering (ELS).
The hydrodynamic radius and the surface charge of the nanovaccine
were evaluated by DLS and ELS with a Zetasizer NanoZS (Malvern
Instruments Ltd., UK). Each sample was diluted 1:50, and 1 mL of
the dilution was pipetted in a disposable polystyrene cuvette (Sarstedt
AG&Co., Germany) to determine the size. The temperature of each
sample was equilibrated to 25 °C before each measurement. About
750 μL of the particle suspension in Milli Q-water (pH 7.4) was
pipetted into a disposable folded capillary cell (DTS1070, Malvern
Ltd., UK).
Cytocompatibility Studies.We assessed the cytocompatibility of
TOPSi@AcDEX@CCM alone or in the presence of two different
concentrations of murine anti-CTLA-4 antibody (In vivo Mab
antimouse CTLA-4, CD152, clone 9D9, Bio X Cell, USA). Briefly,
50 μL of a 4 × 105 cell/mL suspension of JAWS II cells was seeded
into 96-well plates (Corning Inc., USA) and left attaching overnight.
We added 50 μL of the appropriate sample, redispersed in medium, in
each well. The plates were then incubated at 37 °C with 5% CO2. At
the time point, we then added 100 μL of Cell Titer Glo (Promega,
USA) solution to each well. A Varioskan Lux reader (Thermo Fisher
Scientific Inc., USA) was employed to read the resulting
luminescence. Triton X-100 (1%) and 20% of FBS aMEM were
used as positive and negative controls, respectively.
Immunostimulation Assay. We evaluated the immunostimula-
tive properties of the nanovaccine and the effect of the combination
with a check-point inhibitor in JAWS II cells. About 0.7 mL of a 4 ×
105 cell/mL suspension was seeded in 12-well plates (Corning Inc.,
USA) and left attaching overnight. 0.7 mL of the appropriate sample
was added to each well. The plates were then incubated at 37 °C with
5% CO2. Upon each time point, the medium was removed and
centrifuged to recover the cells in suspension, and the adherent cells
were detached with cold PBS-EDTA. The cells were then centrifuged
and suspended in 90 μL of cold PBS. Five μL of APC antimouse
CD80 (BD Biosciences, USA) and 5 μL of PerCP-Cy 5.5 antimouse
CD86 (BioLegend, USA) antibodies were added to each sample. The
samples were incubated for 20 min in the dark at +4 °C. To remove
the unbound antibody, the cells were centrifuged, the supernatant
discarded, and the cell pellet washed twice with cold PBS. We then
suspend the cells in 700 μL of cold PBS and analyzed by flow
cytometry (FACS) on a LSR II (BD Biosciences, USA). A
compensation of the signal from each fluorochrome in the
multistaining analysis was run. Lipopolysaccharide (LPS) and 20%
of FBS aMEM were used as positive and negative controls,
respectively.
Flow Cytometry and Analysis of Tumor-Infiltrating Immune
Cells. Tumors were excised from the euthanized animals, and single
cell suspensions were obtained by gently disrupting the tissue samples
on a cell strainer (70 μm net-size) with a syringe plunger. Samples
were then cryopreserved at −80 °C, by adding 10% of DMSO to cell
suspension, until the day of analysis. Samples were quickly thawed
into a water bath (+37 °C) and washed once in PBS. Anti-CD16/32
antibody was used to block unspecific staining from Fc receptors.
Cells were then stained for 30 min with antibody cocktails on ice.
Next, cells were washed to eliminate excess antibodies and fixed in 4%
of formalin for 10 min on ice. Samples were washed two times and
analyzed by flow cytometry. A Gallios flow cytometer (Beckman
Coulter) was used to acquire the data, and FlowJo (Threestar)
software was used for data analysis. Antibodies from BD-biosciences
were used to stain cells for T-cell (CD8, CD4 and CD3) or DCs
(CD11b, CD11c, CD86 and CD80) specific markers.
Statistical Analysis. Statistical significance was determined using
GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). A
detailed description of the statistical methods used to analyze the data
from each experiment can be found in each figure legend.
ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acsnano.8b09613.
Figures analyzing the in vitro mechanism of activation of







Ermei M. Mak̈ila:̈ 0000-0002-8300-6533
Jarno J. Salonen: 0000-0002-5245-742X
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